Risk-adapted therapy in acute myeloid leukemia

被引：0

作者：

Fiegl, M. ^{[1
]}

Hiddemann, W. ^{[1
]}

机构：

[1] Klinikum Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 3, D-81377 Munich, Germany

来源：

INTERNIST | 2012年 / 53卷 / 04期

关键词：

Leukemia; myeloid; acute; Risk stratification; Induction chemotherapy; Consolidation chemotherapy; Stem cell transplantation; allogeneic; STEM-CELL TRANSPLANTATION; AML-COOPERATIVE-GROUP; HIGH-DOSE CYTARABINE; MINIMAL RESIDUAL DISEASE; PROLONGED MAINTENANCE; COMPLETE REMISSION; INDUCTION THERAPY; PROGNOSTIC-FACTOR; ADULTS; TRIAL;

D O I：

10.1007/s00108-011-2986-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The identification and characterization of an increasing number of chromosomal and molecular aberrations has not only increased the understanding of the pathogenesis of acute myeloid leukemia but also provides the means for a better judgment of prognosis and the direction of therapy. Together with patient-specific factors like age, co-morbidity, and performance status, an individualized risk profile can be used to select the most appropriate therapeutic strategy.

引用

页码：392 / +

页数：7

共 20 条

[1] Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG [J].

Braess, Jan ;

Spiekermann, Karsten ;

Staib, Peter ;

Grueneisen, Andreas ;

Woermann, Bernhard ;

Ludwig, Wolf-Dieter ;

Serve, Hubert ;

Reichle, Albrecht ;

Peceny, Rudolf ;

Oruzio, Daniel ;

Schmid, Christoph ;

Schiel, Xaver ;

Hentrich, Marcus ;

Sauerland, Christina ;

Unterhalt, Michael ;

Fiegl, Michael ;

Kern, Wolfgang ;

Buske, Christian ;

Bohlander, Stefan ;

Heinecke, Achim ;

Baurmann, Herrad ;

Beelen, Dietrich W. ;

Berdel, Wolfgang E. ;

Buechner, Thomas ;

Hiddemann, Wolfgang .

BLOOD, 2009, 113 (17) :3903-3910

[2] Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial [J].

Brune, Mats ;

Castaigne, Sylvie ;

Catalano, John ;

Gehlsen, Kurt ;

Ho, Anthony D. ;

Hofmann, Wolf-Karsten ;

Hogge, Donna E. ;

Nilsson, Bo ;

Or, Reuven ;

Romero, Ana I. ;

Rowe, Jacob M. ;

Simonsson, Bengt ;

Spearing, Ruth ;

Stadtmauer, Edward A. ;

Szer, Jeff ;

Wallhult, Elisabeth ;

Hellstrand, Kristoffer .

BLOOD, 2006, 108 (01) :88-96

[3] Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia [J].

Büchner, T ;

Berdel, WE ;

Schoch, C ;

Haferlach, T ;

Serve, HL ;

Kienast, J ;

Schnittger, S ;

Kern, W ;

Tchinda, J ;

Reichle, A ;

Lengfelder, E ;

Staib, P ;

Ludwig, WD ;

Aul, C ;

Eimermacher, H ;

Balleisen, L ;

Sauerland, MC ;

Heinecke, A ;

Wöermann, B ;

Hiddemann, W .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2480-2489

[4] 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group [J].

Büchner, T ;

Hiddemann, W ;

Berdel, WE ;

Wörmann, B ;

Schoch, C ;

Fonatsch, C ;

Löffler, H ;

Haferlach, T ;

Ludwig, WD ;

Maschmeyer, G ;

Staib, P ;

Aul, C ;

Grüneisen, A ;

Lengfelder, E ;

Frickhofen, N ;

Kern, W ;

Serve, HL ;

Mesters, RM ;

Sauerland, MC ;

Heinecke, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4496-4504

[5] A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment [J].

Burnett, Alan K. ;

Milligan, Donald ;

Prentice, Archie G. ;

Goldstone, Anthony H. ;

McMullin, Mary F. ;

Hills, Robert K. ;

Wheatley, Keith .

CANCER, 2007, 109 (06) :1114-1124

[6] TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics [J].

Chou, Wen-Chien ;

Chou, Sheng-Chieh ;

Liu, Chieh-Yu ;

Chen, Chien-Yuan ;

Hou, Hsin-An ;

Kuo, Yuan-Yeh ;

Lee, Ming-Cheng ;

Ko, Bor-Sheng ;

Tang, Jih-Luh ;

Yao, Ming ;

Tsay, Woei ;

Wu, Shang-Ju ;

Huang, Shang-Yi ;

Hsu, Szu-Chun ;

Chen, Yao-Chang ;

Chang, Yi-Chang ;

Kuo, Yi-Yi ;

Kuo, Kuan-Ting ;

Lee, Fen-Yu ;

Liu, Ming-Chi ;

Liu, Chia-Wen ;

Tseng, Mei-Hsuan ;

Huang, Chi-Fei ;

Tien, Hwei-Fang .

BLOOD, 2011, 118 (14) :3803-3810

[7] Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? [J].

Cornelissen, Jan J. ;

van Putten, Wim L. J. ;

Verdonck, Leo F. ;

Theobald, Matthias ;

Jacky, Emanuel ;

Daenen, Simon M. G. ;

Kooy, Marinus van Marwijk ;

Wijermans, Pierre ;

Schouten, Harry ;

Huijgens, Peter C. ;

van der Lelie, Hans ;

Fey, Martin ;

Ferrant, Augustin ;

Maertens, Johan ;

Gratwohl, Alois ;

Lowenberg, Bob .

BLOOD, 2007, 109 (09) :3658-3666

[8] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].

Doehner, Hartmut ;

Estey, Elihu H. ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Burnett, Alan K. ;

Dombret, Herve ;

Fenaux, Pierre ;

Grimwade, David ;

Larson, Richard A. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel A. ;

Sierra, Jorge ;

Tallman, Martin S. ;

Loewenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2010, 115 (03) :453-474

[9] Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Gattermann, Norbert ;

Germing, Ulrich ;

Sanz, Guillermo ;

List, Alan F. ;

Gore, Steven ;

Seymour, John F. ;

Dombret, Herve ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :562-569

[10] Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy [J].

Grimwade, David ;

Jovanovic, Jelena V. ;

Hills, Robert K. ;

Nugent, Elizabeth A. ;

Patel, Yashma ;

Flora, Rajinder ;

Diverio, Daniela ;

Jones, Katy ;

Aslett, Hannah ;

Batson, Elaine ;

Rennie, Kristian ;

Angell, Roger ;

Clark, Richard E. ;

Solomon, Ellen ;

Lo-Coco, Francesco ;

Wheatley, Keith ;

Burnett, Alan K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3650-3658

← 1 2 →